Related Experiment Video

Updated: Nov 29, 2025

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.9K

Inhibiting RRM2 to enhance the anticancer activity of chemotherapy

Yaqiong Zhan1, Lushun Jiang1, Xuehang Jin1

  • 1State Key Laboratory for Diagnosis and Treatment of Infectious Disease, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 QingChun Road, Hangzhou, Zhejiang 310000, People's Republic of China.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|November 23, 2020
PubMed

Insights

Ribonucleotide reductase M2 (RRM2) promotes tumors and causes chemotherapy resistance. Inhibiting RRM2 can enhance chemotherapy

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ribonucleotide reductase M2 (RRM2) is the small subunit of ribonucleotide reductase.
  • RRM2 overexpression is frequently observed in chemo-resistant cancers and predicts poor prognosis.
  • RRM2 plays a critical role in mediating resistance to various chemotherapeutic agents.

Purpose of the Study:

  • To review the mechanisms driving RRM2 overexpression in cancer.
  • To elucidate the role of RRM2 in chemotherapy resistance.
  • To summarize therapeutic strategies targeting RRM2 for overcoming chemoresistance.

Main Methods:

  • Literature review of studies on RRM2 overexpression mechanisms.
  • Analysis of RRM2's role in mediating drug resistance.
  • Compilation of therapeutic approaches targeting RRM2, including siRNA, inhibitors, and combination therapies.

Main Results:

  • RRM2 overexpression is linked to tumor promotion and chemoresistance.
  • RRM2 activity is a key factor in the efficacy of chemotherapy.
  • Various strategies targeting RRM2 show potential in overcoming resistance and enhancing anticancer effects.

Conclusions:

  • Targeting RRM2, through inhibition or inactivation, is a promising strategy to enhance chemotherapy efficacy.
  • RRM2 can serve as a predictive biomarker for chemosensitivity and patient prognosis.
  • Further research into RRM2-targeted therapies could lead to improved cancer treatment outcomes.
Keywords:
ChemoresistanceChemotherapyKinase inhibitorsRRM2 inhibitorsRibonucleotide reductase subunit M2Small interfering RNA

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K
Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.5K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.3K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
394